Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion type Assertion NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_head.
- NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion description "[We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_provenance.
- NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion evidence source_evidence_literature NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_provenance.
- NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion SIO_000772 25522765 NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_provenance.
- NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion wasDerivedFrom befree-2016 NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_provenance.
- NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_assertion wasGeneratedBy ECO_0000203 NP1249318.RA4d8vZrTJ3bx4TwulGwH8GfGKgBE6YSSPUBlUNQQVWBE130_provenance.